Because various studies have consistently demonstrated superior efficacy and safety of the third-generation aromatase inhibitors (AIs) compared with those of tamoxifen alone in postmenopausal women with ER (+) breast cancer [6, 7], AIs are widely administered as standard adjuvant endocrine therapy in this population [8]. This evidence concerns the gene CYP19A1 and breast cancer.